H
Helen Gogas
Researcher at National and Kapodistrian University of Athens
Publications - 354
Citations - 24375
Helen Gogas is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 53, co-authored 296 publications receiving 18729 citations. Previous affiliations of Helen Gogas include University of Pittsburgh & Aix-Marseille University.
Papers
More filters
Journal ArticleDOI
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert,Georgina V. Long,Benjamin Brady,Caroline Dutriaux,Michele Maio,Laurent Mortier,Jessica C. Hassel,Piotr Rutkowski,Catriona M. McNeil,Ewa Kalinka-Warzocha,Kerry J. Savage,Micaela Hernberg,Céleste Lebbé,Julie Charles,Catalin Mihalcioiu,Vanna Chiarion-Sileni,Cornelia Mauch,Francesco Cognetti,Ana Arance,Henrik Schmidt,Dirk Schadendorf,Helen Gogas,Lotta Lundgren-Eriksson,Christine Horak,Brian Sharkey,Ian M. Waxman,Victoria Atkinson,Paolo A. Ascierto,Abstr Act +28 more
TL;DR: Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation.
Journal ArticleDOI
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber,Mario Mandalà,Michele Del Vecchio,Helen Gogas,Ana Arance,C. Lance Cowey,Stéphane Dalle,Michael Schenker,Vanna Chiarion-Sileni,Ivan Marquez-Rodas,Jean-Jacques Grob,Marcus O. Butler,Mark R. Middleton,Michele Maio,Victoria Atkinson,Paola Queirolo,Rene Gonzalez,Ragini R. Kudchadkar,Michael Smylie,Nicolas Meyer,Laurent Mortier,Michael B. Atkins,Georgina V. Long,Shailender Bhatia,Céleste Lebbé,Piotr Rutkowski,Kenji Yokota,Naoya Yamazaki,Tae M. Kim,Veerle de Pril,J Sabater,Anila Qureshi,James Larkin,Paolo A. Ascierto +33 more
TL;DR: Among patients undergoing resection of stage IIIB, IIIC, or IV melanoma, adjuvant therapy with nivolumab resulted in significantly longer recurrence‐free survival and a lower rate of grade 3 or 4 adverse events than adjuant therapy with ipilimumab.
Journal ArticleDOI
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Georgina V. Long,Daniil Stroyakovskiy,Helen Gogas,Evgeny Levchenko,F. de Braud,James Larkin,Claus Garbe,T. Jouary,Axel Hauschild,Jean-Jacques Grob,V. Chiarion Sileni,Céleste Lebbé,Mario Mandalà,Michael Millward,Ana Arance,Igor Bondarenko,John B. A. G. Haanen,Johan Hansson,Jochen Utikal,Virginia Ferraresi,Nadezhda Kovalenko,Peter Mohr,V. Probachai,Dirk Schadendorf,Paul Nathan,Caroline Robert,Antoni Ribas,Douglas J. DeMarini,Jhangir G. Irani,Michelle Casey,Daniele Ouellet,Anne-Marie Martin,Ngocdiep T. Le,Kiran Patel,Keith T. Flaherty +34 more
TL;DR: A combination of dabraenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic melanoma with BRAF V600E or V600K mutations.
Journal ArticleDOI
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long,Georgina V. Long,Daniil Stroyakovskiy,Helen Gogas,Evgeny Levchenko,Filippo de Braud,James Larkin,Claus Garbe,Thomas Jouary,Axel Hauschild,Jean-Jacques Grob,Vanna Chiarion-Sileni,Céleste Lebbé,Mario Mandalà,Michael Millward,Ana Arance,Igor Bondarenko,John B. A. G. Haanen,Johan Hansson,Jochen Utikal,Jochen Utikal,Virginia Ferraresi,Nadezhda Kovalenko,Peter Mohr,Volodymr Probachai,Dirk Schadendorf,Paul Nathan,Caroline Robert,Caroline Robert,Antoni Ribas,Douglas J Demarini,Jhangir G. Irani,Suzanne Swann,Jeffrey J. Legos,Fan Jin,Bijoyesh Mookerjee,Keith T. Flaherty +36 more
TL;DR: The improvement in overall survival establishes the combination of dabrafenib and trametinib as the standard targeted treatment for BRAF Val600 mutation-positive melanoma.
Journal ArticleDOI
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Caroline Robert,Jean J. Grob,Daniil Stroyakovskiy,Boguslawa Karaszewska,Axel Hauschild,Evgeny Levchenko,Vanna Chiarion Sileni,Jacob Schachter,Claus Garbe,Igor Bondarenko,Helen Gogas,Mario Mandalà,John B A G Haanen,C. Lebbé,Andrzej Mackiewicz,Piotr Rutkowski,Paul Nathan,Antoni Ribas,Michael A. Davies,Keith T. Flaherty,Paul Burgess,Monique Tan,Eduard Gasal,Maurizio Voi,Dirk Schadendorf,Georgina V. Long +25 more
TL;DR: First-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.